US FDA oncology panel to consider broader use of Tarceva and Tykerb
18 November 2009
Sue Sutter
Please Login to read the full article.
18 November 2009
Sue Sutter
sue.sutter@informa.com
The US FDA's oncologic drugs advisory committee will discuss supplemental indications for Roche/ OSI Pharmaceuticals' EGFR-targeted Tarceva (erlotinib) and GlaxoSmithKline's HER2 and EGFR inhibitor Tykerb (lapatinib) on December 16th.
In March, OSI/Roche submitted an sNDA for first-line...
Please Login to read the full article.
RELATED CONTENT
NEWS
- European approval for Roche's Tarceva as first-line in genetically distinct NSCLC
- NICE drug wars: Tarceva vs Iressa, Revlimid vs IFN alpha, Botox vs SoC, and others
- ImmunoGen to raise $84 million, adding own pipeline to Roche-licensed compounds
- Easing of Japanese Tarceva restrictions in NSCLC set to raise pressure on Iressa
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
